IN8bio, Inc.
in8bio.comWhat Do They Do?
Develops gamma-delta T-cell therapies and medicines that activate these cells to treat cancer and autoimmune diseases.
10-K for FY2025, filed Mar 12, 2026We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T…View ↗
We develop ex vivo expanded and activated gamma-delta T cell candidates and TCEs based upon our deep expertise in gamma-delta T cell…View ↗
Most recently we introduced INB-600, our proprietary, internally developed TCE platform. This platform represents a potentially…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$4.8MView ↗
- ▼ −6% (Loss)
- vs −$5.1M in Q2 FY2025
T-cell engagers and autoimmune diseases
The earlier report focused on gamma-delta T-cell product candidates for solid and liquid tumors. The latest report also describes T-cell engagers and programs for autoimmune diseases.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 12, 2026We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell…View ↗
Who Do They Compete With?
Competes with Acepodia USA, Adicet Bio, American Gene Technologies International, Century Therapeutics, CytoMed Therapeutics, Editas Medicine, Enochian BioSciences, Eureka Therapeutics, Expression Therapeutics, Immatics Biotechnologies, Johnson & Johnson, Kiromic Biopharma, OverT Bio, PersonGen BioTherapeutics (Suzhou), PhosphoGam, Regeneron Pharmaceuticals, Sandhill Therapeutics, Senti Biosciences, Shattuck Labs, and Xoma Royalty
10-K for FY2025, filed Mar 12, 2026The field of gamma-delta T cells and T cell engagers is growing rapidly. Our known competitors in the field of allogeneic and gamma-delta T…View ↗
Loading...
